Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2020
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2020, provides an overview of the Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline landscape.
Marburg hemorrhagic fever is a rare, acute infectious which affects both human and nonhuman primates. Symptoms include fever, headache, chills, weakness, diarrhea, stomach pain and weight loss.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Marburgvirus Infections (Marburg Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 19 and 9 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 4 and 2 molecules, respectively.
Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2020, provides an overview of the Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline landscape.
Marburg hemorrhagic fever is a rare, acute infectious which affects both human and nonhuman primates. Symptoms include fever, headache, chills, weakness, diarrhea, stomach pain and weight loss.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Marburgvirus Infections (Marburg Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 19 and 9 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 4 and 2 molecules, respectively.
Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Marburgvirus Infections (Marburg Hemorrhagic Fever) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Marburgvirus Infections - Overview
Marburgvirus Infections - Therapeutics Development
Marburgvirus Infections - Therapeutics Assessment
Marburgvirus Infections - Companies Involved in Therapeutics Development
Marburgvirus Infections - Drug Profiles
Marburgvirus Infections - Dormant Projects
Marburgvirus Infections - Discontinued Products
Marburgvirus Infections - Product Development Milestones
Appendix
Marburgvirus Infections - Overview
Marburgvirus Infections - Therapeutics Development
Marburgvirus Infections - Therapeutics Assessment
Marburgvirus Infections - Companies Involved in Therapeutics Development
Marburgvirus Infections - Drug Profiles
Marburgvirus Infections - Dormant Projects
Marburgvirus Infections - Discontinued Products
Marburgvirus Infections - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development for Marburgvirus Infections (Marburg Hemorrhagic Fever), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by AIkido Pharma Inc, H2 2020
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by ANP Technologies Inc, H2 2020
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by BioCryst Pharmaceuticals Inc, H2 2020
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Collaborations Pharmaceuticals Inc, H2 2020
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Eisai Co Ltd, H2 2020
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Emergent BioSolutions Inc, H2 2020
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Dormant Projects, H2 2020
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Discontinued Products, H2 2020
Number of Products under Development for Marburgvirus Infections (Marburg Hemorrhagic Fever), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by AIkido Pharma Inc, H2 2020
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by ANP Technologies Inc, H2 2020
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by BioCryst Pharmaceuticals Inc, H2 2020
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Collaborations Pharmaceuticals Inc, H2 2020
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Eisai Co Ltd, H2 2020
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Pipeline by Emergent BioSolutions Inc, H2 2020
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Dormant Projects, H2 2020
Marburgvirus Infections (Marburg Hemorrhagic Fever) - Discontinued Products, H2 2020
LIST OF FIGURES
Number of Products under Development for Marburgvirus Infections (Marburg Hemorrhagic Fever), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
COMPANIES MENTIONED
AIkido Pharma Inc
ANP Technologies Inc
BioCryst Pharmaceuticals Inc
Collaborations Pharmaceuticals Inc
Eisai Co Ltd
Emergent BioSolutions Inc
Emergex Vaccines Ltd
Fab’entech SA
Flow Pharma Inc
Fox Chase Chemical Diversity Center Inc
GeoVax Labs Inc
Globavir Biosciences Inc
Greffex Inc
IDBiologics Inc
Immunomodulation Inc
Integrated BioTherapeutics Inc
Intervir Therapeutics
Johnson & Johnson
Mapp Biopharmaceutical Inc
Microbiotix Inc
Phoenix Biotechnology Inc
Profectus BioSciences Inc
Rodos BioTarget GmbH
Soligenix Inc
Number of Products under Development for Marburgvirus Infections (Marburg Hemorrhagic Fever), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020
COMPANIES MENTIONED
AIkido Pharma Inc
ANP Technologies Inc
BioCryst Pharmaceuticals Inc
Collaborations Pharmaceuticals Inc
Eisai Co Ltd
Emergent BioSolutions Inc
Emergex Vaccines Ltd
Fab’entech SA
Flow Pharma Inc
Fox Chase Chemical Diversity Center Inc
GeoVax Labs Inc
Globavir Biosciences Inc
Greffex Inc
IDBiologics Inc
Immunomodulation Inc
Integrated BioTherapeutics Inc
Intervir Therapeutics
Johnson & Johnson
Mapp Biopharmaceutical Inc
Microbiotix Inc
Phoenix Biotechnology Inc
Profectus BioSciences Inc
Rodos BioTarget GmbH
Soligenix Inc
